A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback